Maintenance Notice (12:30 AM - 4:00 AM June 8, 2025): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.198
Maximum quantity allowed is 999
Please select the quantity
Jumonji Domain-containing Histone Demethylase (JHDM) Inhibitor
No.158(July 2013)
Jumonji domain-containing histone demethylase (JHDM) is an enzyme catalyzing the demethylation of
the methylated lysine residue in histone, which regulates the expression of Mdm2 oncogene and p53
anti-oncogene. NCDM-32b (1), developed by Suzuki, Miyata et al., forms NCDM-32 losing a methyl
group of the ester moiety by hydrolytic degradation, and shows an inhibitory activity against JMJD2C, a kind of
JHDM. NCDM-32 inhibits the growth of HCT116 colon cancer cells with a combination of LSD1 inhibitor.
References
- Design, synthesis, enzyme-Inhibitory activity, and effect on human cancer cells of a novel series of Jumonji domain-containing protein 2 histone demethylase inhibitors
Related Compounds
- P0553
- 2,4-Pyridinedicarboxylic Acid Hydrate (= PCA) (*This product is discontinued. Alternatively, Product No. P2416 is available.)
- A2411
- NCL-1•HCl (*This product is discontinued.)
- D4015
- Daminozide
- A2501
- Acetyldinaline
- D4188
- 4-(Dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide (= M 344)
- S0892
- Splitomicin
- T2477
- Trichostatin A
- S0519
- Sodium Butyrate
- P0823
- Valproic Acid
- S0894
- Valproic Acid Sodium Salt
The prices are subject to change without notice. Please confirm the newest price by our online
catalog before placing an order.
In addition, sales products changes with areas. Please understand that a product is not available when the product details page is not displayed.
In addition, sales products changes with areas. Please understand that a product is not available when the product details page is not displayed.